ライフサイエンスコーパス: sentinel node

1 lumpectomy and were found to have a positive sentinel node.

2 ping and an attempt to identify and remove a sentinel node.

3 discovered on frozen section analysis of the sentinel node.

4 e, resulting in intense blue staining of the sentinel node.

5 nation with blue dye for localization of the sentinel node.

6 ng and radioguided probe localization of the sentinel node.

7 e visualization and radiolocalization of the sentinel node.

8 performed in 157 women with a tumor-involved sentinel node.

9 may lead to incorrect identification of the sentinel node.

10 rapy is clear with the finding of a positive sentinel node.

11 ment of some melanoma micrometastasis in the sentinel node.

12 aracterize its uptake by gastric and colonic sentinel nodes.

13 nts (85%), including 21 (55%) with bilateral sentinel nodes.

14 One patient had false-negative sentinel nodes.

15 and blue dyes, investigators are identifying sentinel nodes.

16 in any portion of the breast can drain to IM sentinel nodes.

17 Use of MOVA can improve identification of AX sentinel nodes.

18 ansit times from injection to arrival at the sentinel nodes.

19 r patients with histopathologically negative sentinel nodes.

20 ients with positive nodes had false-negative sentinel nodes.

21 ection was performed if tumor was present in sentinel nodes.

22 patients with a small tumour burden in their sentinel nodes.

23 to identify draining lymphatic channels and sentinel nodes.

24 stasis and 70 patients (68%) with tumor-free sentinel nodes.

25 eive mastectomy and have one to two positive sentinel nodes.

26 s with breast cancer and metastases in their sentinel nodes.

27 s similarity was also found in the number of sentinel nodes (171 in the first study and 173 in the se

28 l of 132 nodes were identified clinically as sentinel nodes; 65 (49%) were both blue and hot, 35 (27%

29 Of the 1425 patients with a positive sentinel node, 744 had been randomly assigned to axillar

30 omy (SLND) has confirmed that tumor-negative sentinel nodes accurately predict tumor-free axillary no

31 Our findings reinforce the concept that sentinel nodes act as pivotal sites for determining prog

32 e which are the best methods for identifying sentinel nodes.Additional information is available at

33 the accuracy of intraoperative evaluation of sentinel nodes after neoadjuvant chemotherapy.

34 eries, so here is a surgeon's perspective on sentinel node and other oncological applications and on

35 tigraphy is reproducible in detection of the sentinel node and with the surgical probe helps effectiv

36 .3+/-4.6% among patients with tumor-positive sentinel nodes and 90.2+/-1.3% among those with tumor-ne

37 e assessed as having pathologically negative sentinel nodes and for whom follow-up data were availabl

38 5 assessable patients, 57 had tumor-positive sentinel nodes and one had an unsuccessful mapping proce

39 t micrometastases in four patients (three in sentinel nodes and one in a nonsentinel node).

40 scintigraphy, but reliable identification of sentinel nodes and their afferent lymph channels require

41 serving therapy and found to have a positive sentinel node, and can also be avoided in patients with

42 han thickness-matched controls, and positive sentinel nodes are limited to patients with thick primar

43 at SLNB after NAC is accurate when 3 or more sentinel nodes are obtained, but long-term outcomes are

44 Approximately one fifth of internal mammary sentinel nodes are pathologic, although most centers do

45 aoperative molecular detection technique for sentinel node assessment via the quantitative measuremen

46 ted a technical success rate for identifying sentinel nodes at 96.2% with a false negative rate of 6.

47 ients with breast cancer who have a positive sentinel node, axillary lymph node dissection is the pre

48 Median tumor volume in positive sentinel node basins was 4.3 mm3 (range, 0.07 to 523 mm3

49 had the lowest rate of pathologic staging by sentinel node biopsy (81.6%-87.4%).

50 diotherapy to the breast alone after BCS and sentinel node biopsy (Group 2) and nine healthy age-matc

51 dity of intraoperative lymphatic mapping and sentinel node biopsy (LM/SNB) for staging the regional n

52 Experience with sentinel node biopsy (SNB) after neoadjuvant chemotherap

53 rovide current recommendations on the use of sentinel node biopsy (SNB) for patients with early-stage

54 Sentinel node biopsy (SNB) has led to an increase in the

55 tive predictive value, the implementation of sentinel node biopsy (SNB) in robot-assisted radical pro

56 Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic fa

57 Worldwide, sentinel node biopsy (SNB) is now a standard staging pro

58 The benefit of adding sentinel node biopsy (SNB) to extended pelvic lymph node

59 ctive review revealed 33 women who underwent sentinel node biopsy after percutaneous core biopsy diag

60 for recent trials establishing the safety of sentinel node biopsy alone in patients with breast cance

61 plete axillary node dissection compared with sentinel node biopsy alone.

62 llary LN dissection could be de-escalated to sentinel node biopsy even in the presence of features su

63 tion, he underwent a wide local excision and sentinel node biopsy for an acral melanoma on his left h

64 Can FDG PET/CT replace sentinel node biopsy for axillary staging?

65 In addition, the technique of dynamic sentinel node biopsy has been refined.

66 Sentinel node biopsy has been shown to extend disease fr

67 Systematic analysis of FS during sentinel node biopsy has not been illuminated in the lit

68 Surgical axillary staging via sentinel node biopsy in patients with benign axillary no

69 Sentinel node biopsy in patients with early breast cance

70 escalating role of nodal micrometastases and sentinel node biopsy in the definition of minimal region

71 est a therapeutic role for lymphatic mapping/sentinel node biopsy in the management and prognosis of

72 From 1998 to 2001, the use of sentinel node biopsy increased more than twofold in the

73 zed the transcriptional profiles of archival sentinel node biopsy specimens obtained from melanoma pa

74 mbers of patients and ideally should include sentinel node biopsy staging.

75 Sentinel node biopsy was successful in 30 women (91%) wi

76 ile carcinoma (n = 9) who were scheduled for sentinel node biopsy were prospectively included.

77 It has been substituted by sentinel node biopsy with dissection only if the sentine

78 -table diagnosis remains a key objective for sentinel node biopsy, and FS detection may be improved b

79 tive radiotherapy are unknown, premastectomy sentinel node biopsy, delayed-immediate reconstruction,

80 with no palpable lymph nodes, compared with sentinel node biopsy, provides no survival benefit and i

81 to omit axillary dissection after a positive sentinel node biopsy, the panel recommends that these pa

82 The patient underwent wide excision and sentinel node biopsy, which showed absence of residual m

83 been shown to improve patient selection for sentinel node biopsy.

84 sually mastectomy with axillary clearance or sentinel node biopsy.

85 ed from intraoperative lymphatic mapping and sentinel node biopsy.

86 ut the risks of surgery or even percutaneous sentinel node biopsy.

87 (RT) following wide local excision (WLE) and sentinel node biopsy.

88 Forty-one patients underwent a sentinel node biopsy.

89 r, and who have 3 or fewer positive nodes on sentinel node biopsy.

90 She undergoes a wide local excision and sentinel node biopsy.

91 ically important application of percutaneous sentinel node biopsy.

92 Furthermore, discussions about the role of sentinel-node biopsy and tamoxifen in disease management

93 rimary melanomas according to the results of sentinel-node biopsy provides important prognostic infor

94 We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly

95 al relapse occurred, or to wide excision and sentinel-node biopsy with immediate lymphadenectomy if n

96 Sentinel-node biopsy, a minimally invasive procedure for

97 with palpable nodes or positive findings on sentinel-node biopsy, and no increased cardiovascular or

98 se (observation group), or wide excision and sentinel-node biopsy, with immediate lymphadenectomy for

99 nfidence interval [CI], 87.5 to 91.9) in the sentinel-node biopsy-only group and 88.7% (95% CI, 86.3

100 ered to 1192 of 1326 patients (89.9%) in the sentinel-node biopsy-only group and to 1058 of 1197 (88.

101 Intraoperative evaluation of the sentinel node can determine the need for axillary dissec

102 Biopsy of sentinel nodes can predict the presence or absence of ax

103 before systemic therapy and suggest that the sentinel node concept is applicable following neoadjuvan

104 Completion ALND was performed only if sentinel nodes contained metastases or if they were not

105 sk of nonsentinel nodal involvement when the sentinel node contains tumor cells.

106 In total, 95% of the sentinel nodes could be intraoperatively visualized by m

107 nd injection), all preoperatively identified sentinel nodes could be localized using radio- and fluor

108 Sentinel nodes could not be distinguished reliably from

109 The number of sentinel nodes detected per patient ranged from 0 to 3 (

110 loid was 91% (the incidence of the number of sentinel nodes detected was 37.5%, 30.3%, 10.7%, and 21.

111 administration of a radiopharmaceutical for sentinel node detection and to characterize its uptake b

112 ommon iliac region is successful to identify sentinel nodes during laparoscopic surgery per hemipelvi

113 She underwent excision and sentinel node evaluation.

114 harvest this first draining node, termed the sentinel node, for examination.

115 r role as reliable markers for identifying a sentinel node from additional secondary lymph nodes that

116 sis (< or =2 mm), compared with 55% when the sentinel node had a macrometastasis (>2 mm).

117 nonsentinel node involvement was 7% when the sentinel node had a micrometastasis (< or =2 mm), compar

118 Patients with positive sentinel nodes have a significantly increased risk for r

119 90.2+/-1.3% among those with tumor-negative sentinel nodes (hazard ratio for death, 2.48; 95% CI, 1.

120 The sentinel node hypothesis assumes that a primary tumor dr

121 The concept of sentinel node identification and lymphatic mapping is al

122 r biopsy, and imaging view on the success of sentinel node identification and on the kinetics of radi

123 is study was to determine the feasibility of sentinel node identification in patients with invasive c

124 In vulvar and cervical carcinomas, sentinel node identification may significantly reduce th

125 e 13 who underwent lymphoscintigraphy twice, sentinel node identification was reproducible.

126 MOVA was compared with the anterior view for sentinel node identification.

127 All 39 patients had at least one sentinel node identified intraoperatively.

128 ive lymphoscintigraphy revealed at least one sentinel node in 33 patients (85%), including 21 (55%) w

129 al injection technique rapidly localizes the sentinel node in breast cancer, is an oncologically soun

130 ymph node dissection (CLND) after a positive sentinel node in patients with melanoma.

131 omponents of a multimarker panel to evaluate sentinel nodes in an on-going, multicenter clinical tria

132 success rates for identifying axillary (AX) sentinel nodes in breast cancer patients using preoperat

133 y is highly reproducible in the detection of sentinel nodes in melanoma patients.

134 apping were highly successful at identifying sentinel nodes in patients undergoing radical hysterecto

135 le pyrogen-free I-methylene blue to identify sentinel nodes in patients with breast cancer.

136 istochemical analysis, of initially negative sentinel nodes in patients with breast cancer.

137 Both sentinel nodes in the left groin were positive for melan

138 Applying IHC to the 157 tumor-free sentinel nodes in these 70 patients showed an additional

139 colloid, leading to the identification of 66 sentinel nodes in total.

140 The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investiga

141 e contained evidence of tumor if all tagged (sentinel) nodes in the same specimen were histopathology

142 er lymphoscintigraphic identification of the sentinel node, intraoperative gamma probe localization a

143 If a primary breast tumor is small and if sentinel node involvement is micrometastatic, then tumor

144 outcomes from randomized trials according to sentinel-node involvement have been lacking.

145 To determine whether the sentinel node is indeed the node most likely to harbor a

146 One sentinel node is negative for metastasis.

147 c mapping followed by lymphadenectomy if the sentinel node is positive.

148 inel node biopsy with dissection only if the sentinel node is positive.

149 If the sentinel node is tumor-free by both H&E and IHC, then th

150 ikely to contain tumor cells if the axillary sentinel node is tumor-free, but as yet no study has exa

151 Risk of positive sentinel nodes is lower in patients with DM compared to

152 location were evaluated for their effects on sentinel node localization and transit times from inject

153 The sentinel node localization approach showed a high negati

154 inical node-negative breast cancer underwent sentinel node localization study as part of a National C

155 y, with partial axillary node dissection and sentinel node mapping.

156 ases from T1/T2 lesions, or in patients with sentinel node metastases from T1a lesions.

157 Overall, sentinel node metastases were detected in 43 (41.8%) of

158 al trial, we randomly assigned patients with sentinel-node metastases detected by means of standard p

159 tion lymph-node dissection for patients with sentinel-node metastases is not clear.

160 ic survival among patients with melanoma and sentinel-node metastases.

161 nonsentinel node metastasis: the size of the sentinel node metastasis and the size of the primary tum

162 Progression occurred in 43% of patients with sentinel node metastasis, regardless of whether the hott

163 ection may not be necessary in patients with sentinel node micrometastases from T1/T2 lesions, or in

164 The incidence of sentinel-node micrometastases was 16.0% (122 of 764 pati

165 m)Tc-DTPA-mannosyl-dextran uptake by colonic sentinel nodes (n = 4) ranged from 0.54% to 2.4% of the

166 Uptake by gastric sentinel nodes (n = 6) ranged from 0.13% to 4.50%; all r

167 aluating the elimination of routine ALND for sentinel-node negative women to minimize the morbidity a

168 idence-based guidelines for the follow-up of sentinel node-negative melanoma patients are lacking.

169 (AJCC) stage-adjusted follow-up schedule for sentinel node-negative melanoma patients is a safe strat

170 Therefore, one H&E sentinel node-negative patient (1.7%) was actually node-

171 Overall, 388 adult patients diagnosed with sentinel node-negative primary melanoma patients were ra

172 and the IHC lymph node conversion rate from sentinel node-negative to sentinel node-positive was 6.4

173 Of the 218 patients with negative sentinel nodes, nonsentinel nodes were positive in 15 (f

174 etween the radioactive counting rates in the sentinel nodes of both scintigraphic studies was observe

175 isualize the lymphatic drainage patterns and sentinel nodes of individual prostate cancer patients.

176 100 patients: 42 patients had metastases in sentinel nodes; of these, 28 (66.7%) had no other involv

177 Frozen section (FS) analysis of sentinel nodes offers potential on-table diagnosis and t

178 N0, oral cancer was tested by correlation of sentinel node pathologic status with that of nodes withi

179 nversion rate from sentinel node-negative to sentinel node-positive was 6.4% (10/157).

180 nts who were tumor-free by H&E actually were sentinel node-positive, and the IHC lymph node conversio

181 P = .001) were significantly associated with sentinel node positivity.

182 ast surgeons were more likely to perform the sentinel node procedure (P = 0.001).

183 The sentinel node procedure was done before (no-NACT) chemot

184 rospective chart review was performed of all sentinel node procedures for breast cancer from 2004 to

185 brid ICG-(99m)Tc-nanocolloid as a tracer for sentinel node procedures.

186 n and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary

187 be more detailed in examining the harvested sentinel node, providing more accurate staging informati

188 The mean number of sentinel nodes removed was 2.1.

189 Of seven patients with no identified sentinel nodes, six had a tumor-negative axilla.

190 olated tumor cells or micrometastases in the sentinel node (SLN).

191 If sentinel node (SN) biopsy (SNB) is accurate in this sett

192 -specific membrane antigen (PSMA) PET/CT and sentinel node (SN) biopsy in PSMA PET/CT-negative patien

193 our ongoing prospective multicenter trial of sentinel node (SN) biopsy indicate a 29.6% rate of micro

194 Sentinel node (SN) biopsy is accurate in operable oral a

195 adio- and fluorescence image guidance during sentinel node (SN) biopsy procedures.

196 hat preoperative US could avoid the need for sentinel node (SN) biopsy, but in most single-institutio

197 , node-negative breast cancer and a positive sentinel node (SN) biopsy.

198 k, or on an extremity who were scheduled for sentinel node (SN) biopsy.

199 CT/CT over planar lymphoscintigraphy (PI) in sentinel node (SN) detection in malignancies with differ

200 99m)Tc-nanocolloid enables both preoperative sentinel node (SN) identification and intraoperative vis

201 LND was determined by comparing the rates of sentinel node (SN) identification and the incidence of S

202 ymphoscintigraphy and SPECT/CT, preoperative sentinel node (SN) identification can be difficult when

203 Increasing evidence supports that the sentinel node (SN) is at greatest risk for harboring met

204 influence of regression on the status of the sentinel node (SN) is controversial.

205 axillary dissection (ALND) in patients whose sentinel node (SN) is tumor-free.

206 mmediate complete lymphadenectomy (CLND) for sentinel node (SN) metastases, and WE plus postoperative

207 The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator provides e

208 with primary cutaneous melanoma, the risk of sentinel node (SN) metastasis varies according to severa

209 arly-stage melanomas with low disease burden sentinel node (SN) micrometastases, namely, American Joi

210 Approximately 20% of sentinel node (SN) positive melanoma patients have addit

211 ve was to assess the diagnostic value of the sentinel node (SN) procedure for lymph node staging in p

212 urgeons at 13 institutions, examined whether sentinel node (SN) sampling accurately predicted LN stat

213 thout supporting evidence, that knowledge of sentinel node (SN) status does not provide more accurate

214 We aimed to identify determinants of sentinel node (SN) status for incorporation into an exte

215 Few sentinel node (SN) studies in ovarian cancer have been r

216 Knowing that the hybrid sentinel node (SN) tracer indocyanine green (ICG)-(99m)T

217 reported frequency of internal mammary (IM) sentinel node (SN) visualization.

218 he microanatomy of lymphatic flow within the sentinel node (SN), and determine the prognostic accurac

219 ve the detection of occult metastases in the sentinel node (SN), compared with hematoxylin and eosin

220 o recent randomized trials for patients with sentinel node (SN)-negative stage IIB or IIC melanoma re

221 in vulvar cancer patients with a metastatic sentinel node (SN).

222 e in the detection of micrometastases in the sentinel node (SN).

223 ter injection of 1% isosulfan blue, and both sentinel nodes (SNs) and non-SNs obtained during primary

224 o ovarian ligaments has been shown to detect sentinel nodes (SNs) in patients with ovarian cancer.

225 isualize the lymphatic drainage patterns and sentinel nodes (SNs) of individual prostate cancer patie

226 Patients with tumor-positive sentinel nodes (SNs) underwent completion dissections.

227 Patients with tumor-positive sentinel nodes (SNs) were considered for completion lymp

228 Sentinel nodes (SNs) were identified using blue dye and/

229 olloid to create a roadmap that depicted all sentinel nodes (SNs).

230 Age, MR, ulceration, LVI, regression, and sentinel node status were independent predictors of surv

231 ee on Cancer staging parameters (T-stage and sentinel node status).

232 axillary radiotherapy in case of a positive sentinel node, stratified by institution.

233 Sentinel nodes subjacent to hot spots were removed.

234 y, investigators have advocated applying the sentinel node technique to patients with cervical, endom

235 n topics is largely confined to a cluster of sentinel nodes that includes influential conspiracy theo

236 pendent prognostic variable in patients with sentinel nodes that were negative on initial examination

237 e that probe-guided resection of radioactive sentinel nodes (the first nodes that receive drainage fr

238 e analyzed to determine transit times to the sentinel node, the number of nodes visualized in early a

239 est that for women with metastases to 1 or 2 sentinel nodes, the radiation and systemic therapy that

240 In six (86%) of seven women with tumor in sentinel nodes, the sentinel nodes were the only nodes w

241 pping and a more detailed examination of the sentinel node to increase the accuracy of axillary stagi

242 oscintigraphic drainage patterns of a hybrid sentinel node tracer consisting of the fluorescent dye i

243 diation), patients with more than 3 positive sentinel nodes undergoing breast-conserving therapy, and

244 axillary metastases, patients with positive sentinel nodes undergoing mastectomy (who do not, as a s

245 m)Tc-DTPA-mannosyl-dextran demonstrated high sentinel node uptake and high concordance with isosulfan

246 ESIGN, SETTING, AND PARTICIPANTS: The SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound)

247 rate for the identification and removal of a sentinel node was 84.8%.

248 The sensitivity of the sentinel node was 87.5% and the negative predictive valu

249 If the sentinel node was free of metastasis by hematoxylin and

250 The sentinel node was identified in 332 patients (93%) and w

251 A sentinel node was identified in all patients.

252 phatic drainage, and in all cases at least 1 sentinel node was identified.

253 The sentinel node was localized in 98.6% of the cases (419/4

254 had false-negative SLN biopsy; that is, the sentinel node was negative, but at least one nonsentinel

255 The sentinel node was successfully identified by blue dye in

256 psy group, the presence of metastases in the sentinel node was the most important prognostic factor;

257 Success in locating the sentinel node was unrelated to tumor size, type, locatio

258 The pathological status of the sentinel nodes was compared with that of the remaining a

259 Identification of AX sentinel nodes was equivalent with MOVA and anterior vie

260 Intraoperative analysis of sentinel nodes was performed using touch imprint and fro

261 i.e., depicted lymphatic channels leading to sentinel nodes) was 10 with 5.0-micron filtration and 19

262 These same sentinel nodes were also identified during the second sc

263 tions were evaluated, and count rates in the sentinel nodes were calculated and compared.

264 Sentinel nodes were detected in 11 of 12 patients, with

265 On average, 1.8 +/- 1.1 sentinel nodes were examined and 20.3 +/- 7.8 nonsentine

266 Sentinel nodes were examined by standard microscopy or i

267 All sentinel nodes were examined intraoperatively with froze

268 All sentinel nodes were excised.

269 Ex vivo, all radioactive sentinel nodes were fluorescent and vice versa.

270 Sentinel nodes were found at surgery in 30 women (91%).

271 the procedure was technically successful if sentinel nodes were found at surgery.

272 Sentinel nodes were found for 312 (96%) of 325 women and

273 Sentinel nodes were found in 12 (80%) of 15 women in the

274 IM or CL sentinel nodes were found in 19 (25%) cases and were not

275 sful radiocolloid localization, and positive sentinel nodes were found in 40 patients (18.6%).

276 asion; clean margins were obtained, and both sentinel nodes were free of cancer.

277 Sentinel nodes were free of tumor in 23 (77%) of 30 wome

278 Sentinel nodes were identifiable by blue color and by ra

279 Sentinel nodes were identified in 100 patients: 42 patie

280 Sentinel nodes were identified in 132 (99%) of 133 patie

281 Sentinel nodes were identified in 458 of 492 (92%) evalu

282 "Hot spots" representing underlying sentinel nodes were identified with a gamma probe.

283 Sentinel nodes were identified with both radioisotope an

284 Sentinel nodes were identified with radioisotope and blu

285 99mTc-sulfur colloid and continued until AX sentinel nodes were identified.

286 Three percent of positive sentinel nodes were in nonaxillary locations.

287 The remaining sentinel nodes were in the common iliac and para-aortic

288 Eighty percent of sentinel nodes were in three pelvic locations: iliac, ob

289 In the 60 patients whose sentinel nodes were metastasis-free by H&E and IHC, 1087

290 The sentinel nodes were outside the axilla in 8 percent of c

291 nts who had SNB and axillary dissection, the sentinel nodes were positive in 125 patients and were th

292 AX sentinel nodes were revealed in 75 (99%) cases.

293 Sentinel nodes were surgically localized using blue dye,

294 even women with tumor in sentinel nodes, the sentinel nodes were the only nodes with tumor.

295 In five of these patients, sentinel nodes were the only positive lymph nodes.

296 SLND was the only axillary surgery if sentinel nodes were tumor-free.

297 TAS removed suspicious palpable and sentinel nodes, whereas imaging-guidance was optional.

298 The accuracy of the sentinel nodes with respect to the positive or negative

299 Intraoperative evaluation of sentinel nodes with touch imprint and frozen section ana

300 t SLND alone in patients with tumor-negative sentinel nodes would achieve axillary control, with mini